InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect Conference
January 06 2022 - 8:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a
research and clinical-stage biomaterials and biotechnology company
with a focus on the treatment of spinal cord injuries, today
announced that Richard Toselli, M.D., President and Chief Executive
Officer, will present at the upcoming virtual H.C. Wainwright
BioConnect Conference, which runs from January 10 – 13, 2022. Dr.
Toselli’s presentation will provide an overview of the company and
will also highlight recent updates to the company’s clinical
program.
A webcast of Dr. Toselli’s presentation will be available on the
Investor Relations - Events section of the company website at
https://investors.invivotherapeutics.com/events, beginning January
10, 2022 at 7:00 am ET. Dr. Toselli and company management will
also be available to participate in one-on-one meetings with
registered investors attending the conference.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and
clinical-stage biomaterials and biotechnology company with a focus
on treatment of spinal cord injuries. The company was founded in
2005 with proprietary technology co-invented by Robert Langer,
Sc.D., Professor at Massachusetts Institute of Technology, and
Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital
and who now is affiliated with Massachusetts General Hospital. The
publicly traded company is headquartered in Cambridge, MA. For more
details, visit www.invivotherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220106005150/en/
Investor: Bret Shapiro, Managing Partner CORE IR
brets@coreir.com (516) 222-2560
Media: Gina Nugent Ten Bridge Communications
gina@tenbridgecommunications.com 617-460-3579
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Aug 2024 to Sep 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Sep 2023 to Sep 2024